- Home
- KF vs ADAG Comparison
KF vs ADAG Comparison
Compare KF & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KF
- ADAG
- Stock Information
- Founded
- KF 1984
- ADAG 2011
- Country
- KF United States
- ADAG China
- Employees
- KF N/A
- ADAG N/A
- Industry
- KF Investment Managers
- ADAG Biotechnology: Pharmaceutical Preparations
- Sector
- KF Finance
- ADAG Health Care
- Exchange
- KF Nasdaq
- ADAG Nasdaq
- Market Cap
- KF 83.7M
- ADAG 81.9M
- IPO Year
- KF N/A
- ADAG 2021
- Fundamental
- Price
- KF $20.90
- ADAG $1.60
- Analyst Decision
- KF
- ADAG Strong Buy
- Analyst Count
- KF 0
- ADAG 1
- Target Price
- KF N/A
- ADAG $8.00
- AVG Volume (30 Days)
- KF 18.4K
- ADAG 15.4K
- Earning Date
- KF 01-01-0001
- ADAG 03-24-2025
- Dividend Yield
- KF N/A
- ADAG N/A
- EPS Growth
- KF N/A
- ADAG N/A
- EPS
- KF N/A
- ADAG N/A
- Revenue
- KF N/A
- ADAG $103,204.00
- Revenue This Year
- KF N/A
- ADAG $6,488.89
- Revenue Next Year
- KF N/A
- ADAG $57.50
- P/E Ratio
- KF N/A
- ADAG N/A
- Revenue Growth
- KF N/A
- ADAG N/A
- 52 Week Low
- KF $18.30
- ADAG $1.33
- 52 Week High
- KF $25.56
- ADAG $3.58
- Technical
- Relative Strength Index (RSI)
- KF 57.20
- ADAG 51.88
- Support Level
- KF $20.77
- ADAG $1.51
- Resistance Level
- KF $21.48
- ADAG $1.74
- Average True Range (ATR)
- KF 0.34
- ADAG 0.10
- MACD
- KF 0.10
- ADAG 0.03
- Stochastic Oscillator
- KF 62.09
- ADAG 61.84
About KF Korea Fund Inc. (The) New
Korea Fund Inc is a closed-end, non-diversified management investment company. Its investment objective is to seek long-term capital appreciation through investment in securities, equity securities, of Korean companies. Its portfolio consists of the different sectors such as the auto components, banks, beverages, chemicals, aerospace and defense, insurance, machinery, and others.
About ADAG Adagene Inc.
Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.